Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Illinois

CNS medication trials in Illinois

79 CNS medication studies are recruiting participants at sites in 18 cities across Illinois as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Illinois city with a recruiting study

By research area: Depression (26), Schizophrenia (19), Parkinson's Disease (10), Epilepsy (8), Migraine (7), Multiple Sclerosis (6), Bipolar Disorder (3).

Chicago (62), Naperville (8), Skokie (4), Springfield (4), Warrenville (3), Evanston (2), Flossmoor (2), Arlington Heights (1), Carterville (1), Elgin (1), Gurnee (1), Hinsdale (1), Hoffman Estates (1), Northbrook (1), Oak Brook (1), Oak Lawn (1), Orland Park (1), Peoria (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in Illinois

Basic details from each study's public record (the 12 most recently updated of 79). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Recruiting in
    Warrenville
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Recruiting in
    Chicago
    Registry record
    NCT06793397 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Illinois on ClinicalTrials.gov.

Schizophrenia: recently updated in Illinois

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Chicago
    Registry record
    NCT07288567 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Illinois on ClinicalTrials.gov.

Parkinson's disease: recently updated in Illinois

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Chicago · Hinsdale · Peoria
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Chicago
    Registry record
    NCT06841354 · updated
  3. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Chicago
    Registry record
    NCT06952504 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Carterville
    Registry record
    NCT06966700 · updated
  5. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Recruiting in
    Arlington Heights · Evanston
    Registry record
    NCT06989112 · updated
  6. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Skokie
    Registry record
    NCT06345729 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Illinois on ClinicalTrials.gov.

Epilepsy: recently updated in Illinois

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    Springfield
    Registry record
    NCT07563881 · updated
  2. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    Chicago
    Registry record
    NCT07594119 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Illinois on ClinicalTrials.gov.

Migraine: recently updated in Illinois

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Gurnee · Skokie
    Registry record
    NCT07816367 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Illinois on ClinicalTrials.gov.

Ask about studies in Illinois

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call